Altered surfactant protein-A expression in type II pneumocytes in COPD

Chest

Volumn 137, Issue 1, 2010, Pages 37-45

  Vlachaki, Eleni M ^a   Koutsopoulos, Anastassios V ^a   Tzanakis, Nikolaos ^a   Neofytou, Eirini ^a   Siganaki, Marianna ^a   Drositis, Ioannis ^a   Moniakis, Andreas ^a   Schiza, Sophia ^a   Siafakas, Nikolaos M ^a   Tzortzaki, Eleni G ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN; SURFACTANT PROTEIN A;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS MACROPHAGE; LUNG BIOPSY; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 74949086341     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1029     Document Type: Article

References (38)

1. Kishore U, Greenhough TJ, Waters P, et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol. 2006;43(9):1293-1315.
2. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc. 2007;4(3):252-257.
3. Fabbri L, Pauwels RA, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD. 2004;1(1):105-141, discussion 103-104.
4. Otto-Verberne CJ, Ten Have-Opbroek AA, Franken C, Hermans J, Dijkman JH. Protective effect of pulmonary surfactant on elastase-induced emphysema in mice. Eur Respir J. 1992;5(10):1223-1230.
5. Wirtz HR, Schmidt M. Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. Eur Respir J. 1996;9(1):24-32.
6. Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest. 1996;109(4):1006-1009.
7. Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y, Nishimura M. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J. 2004;24(6): 964-970.
8. Guo X, Lin HM, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J. 2001;18(3):482-490.
9. Anzueto A, Jubran A, Ohar JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA. 1997;278(17): 1426-1431.
10. Bernhard W, Haslam PL, Floros J. From birds to humans: new concepts on airways relative to alveolar surfactant. Am J Respir Cell Mol Biol. 2004;30(1):6-11.
11. Milic-Emili J. Does mechanical injury of the peripheral airways play a role in the genesis of COPD in smokers? COPD. 2004;1(1):85-92.
12. Zervou M, Tzortzaki EG, Makris D, et al. Differences in microsatellite DNA level between asthma and chronic obstructive pulmonary disease. Eur Respir J. 2006;28(3):472-478.
13. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
14. Kishore U, Bernal AL, Kamran MF, et al. Surfactant proteins SP-A and SP-D in human health and disease. Arch Immunol Ther Exp (Warsz). 2005;53(5):399-417.
15. Garvey J. Infant respiratory distress syndrome. Am J Nurs. 1975;75(4):614-617.
16. Günther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med. 1996;153(1):176-184.
17. Subramaniam S, Whitsett JA, Hull W, Gairola CG. Alteration of pulmonary surfactant proteins in rats chronically exposed to cigarette smoke. Toxicol Appl Pharmacol. 1996;140(2):274-280.
18. Sulkowski S, Nowak HF, Szynaka B. Alveolar epithelial cells in experimental lung emphysema. Ultrastructural analysis of cells in situ in TEM. Exp Toxicol Pathol. 1994;45(8):513-518.
19. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672-688.
20. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5(1):58-68.
21. Sorensen GL, Husby S, Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology. 2007;212(4-5):381-416.
22. Robin M, Dong P, Hermans C, Bernard A, Bersten AD, Doyle IR. Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur Respir J. 2002;20(5):1152-1161.
23. Hu QJ, Xiong SD, Zhang HL, et al. Altered surfactant protein A gene expression and protein homeostasis in rats with emphysematous changes. Chin Med J (Engl). 2008;121(13): 1177-1182. [Engl].
24. Hu Q, Zhang H, Xiong S, et al. The alteration and significance of surfactant protein A in rats chronically exposed to cigarette smoke. J Huazhong Univ Sci Technolog Med Sci. 2008;28(2):128-131.
25. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276.
26. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269-280.
27. Siafakas NM. "In the beginning" of COPD. Is evolution important? Am J Respir Crit Care Med. 2007;175(5):423-424.
28. Tzortzaki EG, Siafakas NM. A hypothesis for the initiation of COPD. Eur Respir J. 2009;34(2):310-315.
29. Siafakas NM, Tzortzaki EG, Sourvinos G, et al. Microsatellite DNA instability in COPD. Chest. 1999;116(1):47-51.
30. Chizhikov VV, Chikina SIu, Tatosian AG, Chuchalin AG, Zborovskaia IB. [Development of chronic obstructive pulmonary disease correlates with mini- and microsatellite locus instability]. Genetika. 2003;39(5):694-701.
31. Makris D, Tzanakis N, Damianaki A, et al. Microsatellite DNA instability and COPD exacerbations. Eur Respir J. 2008;32(3):612-618.
32. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653.
33. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37(5):542-546.
34. Uzaslan E, Stuempel T, Ebsen M, et al. Surfactant protein A detection in primary pulmonary adenocarcinoma without bronchioloalveolar pattern. Respiration. 2005;72(3):249-253.
35. Kobayashi H, Kanoh S, Motoyoshi K. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers. 2008;13(4):385-392.
36. Nomori H, Horio H, Fuyuno G, Kobayashi R, Morinaga S, Suemasu K. Serum surfactant protein A levels in healthy individuals are increased in smokers. Lung. 1998;176(6): 355-361.
37. Shibata Y, Abe S, Inoue S, et al. Altered expression of anti-microbial molecules in cigarette smoke-exposed emphysematous mice lungs. Respirology. 2008;13(7):1061-1065.
38. Ohlmeier S, Vuolanto M, Toljamo T, et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res. 2008;7(12):5125-5132.